CLS Therapeutics Amends 13D Filing for Xenetic Biosciences

TL;DR

CLS Therapeutics just updated its 13D filing for Xenetic Biosciences, looks like they're increasing their stake.

AI Summary

CLS Therapeutics LLC, led by Georgy Tetz, filed an amendment (No. 2) to its Schedule 13D on March 18, 2024, regarding its holdings in Xenetic Biosciences, Inc. The filing indicates a change in beneficial ownership, with CLS Therapeutics now holding a significant stake in the company.

Why It Matters

This filing signals a potential shift in control or influence over Xenetic Biosciences, which could impact its strategic direction and shareholder value.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate activist investor activity or potential takeovers, introducing uncertainty.

Key Players & Entities

• CLS Therapeutics LLC (company) — Filing entity
• Xenetic Biosciences, Inc. (company) — Subject company
• Georgy Tetz (person) — CEO of CLS Therapeutics LLC
• Dmitry Genkin (person) — Group member
• M. Scott Maguire (person) — Group member
• Victor Tets (person) — Group member

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $90,000 — gregate purchase price of approximately $90,000. Such shares were purchased using Mr. G

Filing Documents

• ea0202011-13da2cls_xenetic.htm (SC 13D/A) — 91KB
• ea020201101ex99-1_xenetic.htm (EX-99.1) — 10KB
• 0001213900-24-023384.txt ( ) — 102KB

From the Filing

SC 13D/A 1 ea0202011-13da2cls_xenetic.htm AMENDMENT NO. 2 TO SCHEDULE 13D UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Xenetic Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 984015503 (CUSIP Number) CLS Therapeutics LLC. Attention: Georgy Tetz, CEO 180 Varick street New York, NY 10014 (646) 617-3088 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) March 18, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 984015503 1. Names of Reporting Persons. CLS Therapeutics, LLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. 4. Source of Funds (See Instructions) OO 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 85,000* 8. Shared Voting Power 9. Sole Dispositive Power 85,000* 10. Shared Dispositive Power 11. Aggregate Amount Beneficially Owned by Each Reporting Person 85,000 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 5.5% (see Item 5) 14. Type of Reporting Person (See Instructions) OO * CLS Therapeutics LLC, an indirect wholly-owned subsidiary of CLS Therapeutics Ltd., owns 85,000 shares of the Common Stock of the Issuer. As the ultimate parent of CLS Therapeutics LLC, CLS Therapeutics Ltd. may exercise voting and dispositive power over these shares. 1 CUSIP No. 984015503 1. Names of Reporting Persons. CLS Therapeutics Ltd. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. 4. Source of Funds (See Instructions) OO 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Guernsey, UK Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 147,500* 8. Shared Voting Power 9. Sole Dispositive Power 147,500* 10. Shared Dispositive Power 11. Aggregate Amount Beneficially Owned by Each Reporting Person 147,500 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 9.6% (see Item 5) 14. Type of Reporting Person (See Instructions) CO * CLS Therapeutics LLC, an indirect wholly-owned subsidiary of CLS Therapeutics Ltd., owns 85,000 shares of the Common Stock of the Issuer. As the ultimate parent of CLS Therapeutics LLC, CLS Therapeutics Ltd. may exercise voting and dispositive power over these shares. 2 CUSIP No. 984015503 1. Names of Reporting Persons. Dmitry Genkin 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. 4. Source of Funds (See Instructions) OO; PF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Israel Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 68,464 8. Shared Voting Power 147,500* 9. Sole Dispositive Power 68,464 10. Shared Dispositive Power 147,500* 11. Aggregate Amount Beneficially Owned by Each Reporting Person 215,964 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 14.0% (see Item 5) 14. Type of Reporting Person (See Instructions) IN * Dmitry Genkin along with the Victor Tets and Georgy Tets may exercise votin

View Full Filing

View this SC 13D/A filing on SEC EDGAR